Skip to main content

Advertisement

Fig. 1 | Trials

Fig. 1

From: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial

Fig. 1

Primary and key secondary outcomes of the AMBITION Step I phase-II randomised controlled trial. The figure shows: (a) all three short-course treatment arms were non-inferior to control; (b) EFA and the individual patient slopes over the initial 14 days of treatment; and (c) all three short-course treatment arms remained non-inferior to control when controlling for baseline fungal burden (QCC), baseline CD4 count, baseline mental status, QCC and CD4 count, QCC count, CD4 count, mental status and QCC, CD4 count, mental status, sex, age and ART status [26]

Back to article page